Bullish
Eli Lilly's stock rises 1.52% to $1,263.34 amid new vaccine collaboration
Eli Lilly's stock increased by 1.52% to $1,263.34 on August 21, 2026, following the announcement of a new collaboration with Amplitude Therapeutics to develop trans-amplifying RNA vaccines for infectious diseases. This partnership is expected to leverage Lilly's global development and commercialization capabilities, potentially enhancing its vaccine portfolio.
Key points
- Eli Lilly's stock price rose 1.52% to $1,263.34 on August 21, 2026.
- Eli Lilly and Amplitude Therapeutics announced a collaboration to develop trans-amplifying RNA vaccines for infectious diseases.
Sources
AI-generated from public news sources. Not financial advice.
